JP2009513165A - Ｐｌｇａマトリックス中に分散された熱不安定性活性成分を含有する皮下インプラントを製造するための可塑剤としてのエタノールの使用 - Google Patents
Ｐｌｇａマトリックス中に分散された熱不安定性活性成分を含有する皮下インプラントを製造するための可塑剤としてのエタノールの使用 Download PDFInfo
- Publication number
- JP2009513165A JP2009513165A JP2006516183A JP2006516183A JP2009513165A JP 2009513165 A JP2009513165 A JP 2009513165A JP 2006516183 A JP2006516183 A JP 2006516183A JP 2006516183 A JP2006516183 A JP 2006516183A JP 2009513165 A JP2009513165 A JP 2009513165A
- Authority
- JP
- Japan
- Prior art keywords
- plga
- weight
- ethanol
- plasticized
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 170
- 239000007943 implant Substances 0.000 title claims abstract description 38
- 238000007920 subcutaneous administration Methods 0.000 title claims abstract description 38
- 239000004480 active ingredient Substances 0.000 title claims abstract description 27
- 239000004014 plasticizer Substances 0.000 title claims abstract description 15
- 239000011159 matrix material Substances 0.000 title claims abstract description 6
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 title claims abstract 31
- 238000004519 manufacturing process Methods 0.000 claims abstract description 33
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 24
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 24
- 239000000203 mixture Substances 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 9
- 238000000227 grinding Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000001415 gene therapy Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 238000001125 extrusion Methods 0.000 abstract description 12
- 238000009835 boiling Methods 0.000 abstract description 2
- 229920000642 polymer Polymers 0.000 description 39
- 102000002265 Human Growth Hormone Human genes 0.000 description 10
- 108010000521 Human Growth Hormone Proteins 0.000 description 10
- 239000000854 Human Growth Hormone Substances 0.000 description 10
- 239000011248 coating agent Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 239000000843 powder Substances 0.000 description 7
- 229960004532 somatropin Drugs 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 238000001542 size-exclusion chromatography Methods 0.000 description 6
- 238000004811 liquid chromatography Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 3
- 108010078049 Interferon alpha-2 Proteins 0.000 description 3
- 102100039350 Interferon alpha-7 Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/141—Plasticizers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001302A ITMI20031302A1 (it) | 2003-06-26 | 2003-06-26 | Uso di etanolo come plasticizzante per preparare impianti sottocutanei contenenti principi attivi termolabili dispersi in una matrice di plga. |
| PCT/EP2004/051226 WO2005000277A1 (en) | 2003-06-26 | 2004-06-24 | Use of ethanol as plasticizer for preparing subcutaneous implants containing thermolabile active principles dispersed in a plga matrix |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009513165A true JP2009513165A (ja) | 2009-04-02 |
| JP2009513165A5 JP2009513165A5 (enExample) | 2011-05-06 |
Family
ID=30131301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006516183A Pending JP2009513165A (ja) | 2003-06-26 | 2004-06-24 | Ｐｌｇａマトリックス中に分散された熱不安定性活性成分を含有する皮下インプラントを製造するための可塑剤としてのエタノールの使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8206621B2 (enExample) |
| EP (1) | EP1638534B1 (enExample) |
| JP (1) | JP2009513165A (enExample) |
| KR (1) | KR101143771B1 (enExample) |
| CN (1) | CN100509060C (enExample) |
| AT (1) | ATE398447T1 (enExample) |
| AU (1) | AU2004251456B2 (enExample) |
| BR (1) | BRPI0411759A (enExample) |
| CA (1) | CA2530117C (enExample) |
| CY (1) | CY1108346T1 (enExample) |
| DE (1) | DE602004014496D1 (enExample) |
| ES (1) | ES2308195T3 (enExample) |
| IT (1) | ITMI20031302A1 (enExample) |
| MX (1) | MXPA05013697A (enExample) |
| PL (1) | PL1638534T3 (enExample) |
| PT (1) | PT1638534E (enExample) |
| WO (1) | WO2005000277A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016530252A (ja) * | 2013-08-09 | 2016-09-29 | ロケート・セラピューティクス・リミテッド | 組成物および送達系 |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7666445B2 (en) | 2000-10-20 | 2010-02-23 | The Trustees Of The University Of Pennsylvania | Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use |
| US8221778B2 (en) | 2005-01-12 | 2012-07-17 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
| AU2006269927B2 (en) * | 2004-01-12 | 2013-05-16 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
| US8329203B2 (en) | 2004-01-12 | 2012-12-11 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
| AU2005325213B2 (en) | 2004-08-04 | 2010-10-07 | Evonik Operations Gmbh | Methods for manufacturing delivery devices and devices thereof |
| ITMI20061539A1 (it) * | 2006-08-02 | 2008-02-03 | Mediolanum Pharmaceuticals Ltd | Impianti sottocutanei in grado di rilasciare il principio attivo per un periodo prolungato di tempo |
| JP5419699B2 (ja) | 2006-10-31 | 2014-02-19 | エボニック コーポレイション | 球状化されたポリマー粒子 |
| JP5502751B2 (ja) | 2007-12-20 | 2014-05-28 | エボニック コーポレイション | 低残留溶媒濃度を有する微粒子を調製するためのプロセス |
| CN102281870B (zh) * | 2008-12-10 | 2015-03-04 | 安徽中人科技有限责任公司 | 新型控释组合物 |
| CA2804035A1 (en) * | 2010-06-30 | 2012-01-05 | Evonik Degussa Corporation | Implant processing methods for thermally labile and other bioactive agents and implants prepared from same |
| CN103623415B (zh) * | 2013-12-04 | 2015-03-25 | 北京诺康达医药科技有限公司 | 一种用于生物多肽制剂的plga与乙醇的复合物 |
| US20170231916A1 (en) * | 2014-08-04 | 2017-08-17 | Janssen Sciences Ireland Uc | Compacted solid dosage form |
| GB201702475D0 (en) * | 2017-02-15 | 2017-03-29 | Locate Therapeutics Ltd | Tissue scaffold and scaffold composition |
| ES2938608T3 (es) * | 2017-09-20 | 2023-04-13 | Tillotts Pharma Ag | Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0549629A (ja) * | 1991-08-23 | 1993-03-02 | Konica Corp | 医用放射線画像読影装置 |
| US5520923A (en) * | 1994-09-19 | 1996-05-28 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
| JP2002531486A (ja) * | 1998-12-10 | 2002-09-24 | メディオラヌム ファルマチェウティチ ソシエタ ペル アチオニ | 放出時間が延長された皮下インプラントを製造するのに適したペプチドとポリ乳酸グリコール酸とを含む組成物 |
| JP2005514350A (ja) * | 2001-11-14 | 2005-05-19 | アルザ・コーポレーション | 注入可能なデポー組成物 |
-
2003
- 2003-06-26 IT IT001302A patent/ITMI20031302A1/it unknown
-
2004
- 2004-06-24 AT AT04741884T patent/ATE398447T1/de active
- 2004-06-24 ES ES04741884T patent/ES2308195T3/es not_active Expired - Lifetime
- 2004-06-24 AU AU2004251456A patent/AU2004251456B2/en not_active Ceased
- 2004-06-24 PT PT04741884T patent/PT1638534E/pt unknown
- 2004-06-24 PL PL04741884T patent/PL1638534T3/pl unknown
- 2004-06-24 CA CA2530117A patent/CA2530117C/en not_active Expired - Fee Related
- 2004-06-24 DE DE602004014496T patent/DE602004014496D1/de not_active Expired - Lifetime
- 2004-06-24 US US10/562,707 patent/US8206621B2/en not_active Expired - Fee Related
- 2004-06-24 JP JP2006516183A patent/JP2009513165A/ja active Pending
- 2004-06-24 CN CNB2004800177773A patent/CN100509060C/zh not_active Expired - Fee Related
- 2004-06-24 EP EP04741884A patent/EP1638534B1/en not_active Expired - Lifetime
- 2004-06-24 WO PCT/EP2004/051226 patent/WO2005000277A1/en not_active Ceased
- 2004-06-24 BR BRPI0411759-0A patent/BRPI0411759A/pt not_active IP Right Cessation
- 2004-06-24 KR KR1020057024514A patent/KR101143771B1/ko not_active Expired - Fee Related
- 2004-06-24 MX MXPA05013697A patent/MXPA05013697A/es active IP Right Grant
-
2008
- 2008-09-17 CY CY20081101000T patent/CY1108346T1/el unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0549629A (ja) * | 1991-08-23 | 1993-03-02 | Konica Corp | 医用放射線画像読影装置 |
| US5520923A (en) * | 1994-09-19 | 1996-05-28 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
| JP2002531486A (ja) * | 1998-12-10 | 2002-09-24 | メディオラヌム ファルマチェウティチ ソシエタ ペル アチオニ | 放出時間が延長された皮下インプラントを製造するのに適したペプチドとポリ乳酸グリコール酸とを含む組成物 |
| JP2005514350A (ja) * | 2001-11-14 | 2005-05-19 | アルザ・コーポレーション | 注入可能なデポー組成物 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016530252A (ja) * | 2013-08-09 | 2016-09-29 | ロケート・セラピューティクス・リミテッド | 組成物および送達系 |
Also Published As
| Publication number | Publication date |
|---|---|
| PT1638534E (pt) | 2008-09-29 |
| KR20060079146A (ko) | 2006-07-05 |
| ITMI20031302A1 (it) | 2004-12-27 |
| ATE398447T1 (de) | 2008-07-15 |
| HK1089954A1 (en) | 2006-12-15 |
| ES2308195T3 (es) | 2008-12-01 |
| AU2004251456B2 (en) | 2009-12-03 |
| MXPA05013697A (es) | 2006-05-17 |
| US20060171987A1 (en) | 2006-08-03 |
| EP1638534A1 (en) | 2006-03-29 |
| PL1638534T3 (pl) | 2009-02-27 |
| KR101143771B1 (ko) | 2012-05-11 |
| CA2530117C (en) | 2012-01-10 |
| WO2005000277A1 (en) | 2005-01-06 |
| CY1108346T1 (el) | 2014-02-12 |
| ITMI20031302A0 (it) | 2003-06-26 |
| EP1638534B1 (en) | 2008-06-18 |
| CA2530117A1 (en) | 2005-01-06 |
| DE602004014496D1 (de) | 2008-07-31 |
| US8206621B2 (en) | 2012-06-26 |
| CN1812770A (zh) | 2006-08-02 |
| CN100509060C (zh) | 2009-07-08 |
| AU2004251456A1 (en) | 2005-01-06 |
| BRPI0411759A (pt) | 2006-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009513165A (ja) | Ｐｌｇａマトリックス中に分散された熱不安定性活性成分を含有する皮下インプラントを製造するための可塑剤としてのエタノールの使用 | |
| US4849141A (en) | Method for producing sustained release formulation | |
| JP3445283B2 (ja) | ヒアルロン酸の微細粒子中に封入された薬物の徐放性組成物 | |
| US5081156A (en) | Sustained-release preparation | |
| CN1822816A (zh) | 可植入的弹性体储库组合物、其用途以及制备方法 | |
| CN1157562A (zh) | 含有一种肽金属盐的缓释制剂 | |
| JP2011068670A (ja) | 短期間デポ調剤 | |
| TW457099B (en) | Sustained release composition of animal growth hormone and process for preparation thereof | |
| JP4683319B2 (ja) | 徐放性製剤用の分散剤 | |
| RU2161954C2 (ru) | Быстрорастворяющиеся во рту лекарственные формы | |
| JP2009513165A5 (enExample) | ||
| AU2006214913A1 (en) | Sustained release composition of protein drug | |
| JPS60112713A (ja) | 有用な徐放性注射剤 | |
| JP7731140B2 (ja) | 制御された活性物質放出のための押出型デポ剤 | |
| HK1089954B (en) | Use of ethanol as plasticizer for preparing subcutaneous implants containing thermolabile active principles dispersed in a plga matrix | |
| KR100329336B1 (ko) | 히아루론산을 이용한 단백질 약물의 서방성 미세 입자 제형 | |
| JP2641755B2 (ja) | コントロールリリース製剤 | |
| CN114794309A (zh) | 一种含酸化剂的饲料添加剂及其制备方法和应用 | |
| JPH0372046B2 (enExample) | ||
| JPH05246879A (ja) | 長期徐放性製剤 | |
| HK1020885B (en) | Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101019 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110117 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110124 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110218 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110225 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20110317 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110607 |